Bayer Puts Breakup Talk on Ice as Pharma Carries a Lopsided Quarter

Bill Anderson has drawn a line under the restructuring era at Bayer. The chief executive now treats the group's overhaul as finished and has parked any separation of the company for the time being, according to Reuters — a signal that innovation and debt reduction, rather than fresh structural surgery, will define the next chapter. For shareholders, the test has simply moved: the slimmer organisation now has to prove it can deliver better results and real financial relief on a sustained basis.

The headcount tells the story of how far the shake-up has gone. Roughly 14,000 positions have been cut since 2023, and the number of managers has come down from 16,000 to 4,500. Anderson regards the deep intervention in the organisation as complete. That does not mean hiring has frozen, however. Bayer still expects the workforce to shrink further over the next three to four years, so the end of the reorganisation is not the same thing as the end of job cuts.

Nor is a breakup on the agenda. According to Fierce Pharma, Anderson does not see a split between the pharmaceuticals and agriculture businesses as a priority. The focus instead sits on the drug division's growth drivers and on artificial intelligence. Keeping the group intact is therefore, for now, an operating challenge rather than an imminent transaction.

A quarter of two halves

Support for that course arrived with the third-quarter 2026 figures. Sales in the pharmaceuticals division rose 8% to EUR 4.68 billion, while EBITDA before special items in the unit climbed 23.6% to EUR 1.292 billion — profit growing faster than revenue, and a concrete sign of improved earnings power. Bayer lifted its full-year 2026 forecast for the division's EBITDA margin to 25% to 27%.

Should investors sell immediately? Or is it worth buying Bayer?

At group level, revenue reached EUR 10.053 billion, up 4.1% year on year, and EBITDA before special items advanced 6.9% to EUR 1.615 billion. Investors liked what they saw: the stock gained 4.0% on the day.

The picture darkens outside pharma. Crop Science saw EBITDA before special items fall 41.3% to EUR 101 million, and Consumer Health posted a 4.4% decline in earnings. A strong drug business alone does not amount to a recovery across the whole company — precisely the yardstick by which Anderson's decision to keep Bayer together will be measured.

The bottom line remains weighed down. Bayer reported a net loss of EUR 672 million, with impairments on Xofigo and Claritin totalling EUR 522 million. Operating progress and a positive group result, in other words, are still two different things.

Debt, guidance and the courtroom

Management also raised its sights for the year. Group EBITDA before special items is now expected at EUR 9.8 billion to EUR 10.3 billion, and the free-cash-flow forecast was improved by EUR 1.0 billion to between minus EUR 1.5 billion and minus EUR 0.5 billion — better, but still negative.

JPMorgan reaffirmed its "Overweight" rating on Bayer following the numbers, keeping a price target of EUR 61.

Bayer at a turning point? This analysis reveals what investors need to know now.

Debt reduction sits explicitly among Anderson's priorities. Net financial debt stood at around EUR 31.1 billion at the end of September, and Bayer expects EUR 28 billion to EUR 29 billion by year-end — a forecast, not yet a balance-sheet fact.

Legal uncertainty lingers alongside it. Court approval of the USD 7.25 billion glyphosate settlement is still outstanding, with Bayer anticipating a decision before Christmas, Reuters reported. Business Insider, meanwhile, has reported on PCB claims tied to the Monsanto acquisition, for which Bayer has already set aside billions. Anderson expects further proceedings in the coming quarters.

The organisational chapter may be closed in the chief executive's view. The financial one is not. What counts for the investment case now is broader-based operating progress, actual deleveraging and how the legal burden develops — not a near-term split.

Ad

Bayer Stock: New Analysis - 3 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...